A research team from the University of Colorado Boulder, the University of Colorado Anschutz, and Colorado State University has developed a set of experimental therapies that may be able to reverse osteoarthritis and repair damaged joints within weeks.

Axar.az reports that the findings, supported by the U.S. Advanced Research Projects Agency for Health (ARPA-H), suggest that a single regenerative injection or biomaterial-based treatment could prompt the body to restore damaged cartilage and bone tissue—offering a potential alternative to joint replacement surgery.

Osteoarthritis, a degenerative disease affecting roughly one in six adults over the age of 30 worldwide, occurs when cartilage that cushions joints gradually breaks down, leading to pain, stiffness, and loss of mobility. Currently, patients typically rely on pain management or invasive joint replacement procedures, as no curative treatment exists.

Two Experimental Approaches

The Colorado-based team is pursuing two main therapeutic strategies. The first involves repurposing an existing FDA-approved drug and delivering it through a patented particle-based system that allows sustained release inside the joint over time. This injectable treatment is designed to reduce inflammation and stimulate repair processes in damaged tissue.

The second approach focuses on a biomaterial “repair kit” containing engineered proteins that can be injected into affected areas. Once applied, the material hardens in place and recruits the body’s own progenitor cells to rebuild damaged cartilage and bone structures.

In animal models, joints treated with the injection showed restoration to a healthy state within four to eight weeks. In cases involving structural damage, researchers observed what they described as “full regeneration and repair” of the affected tissue.

Rapid Progress Under ARPA-H Program

The research is being developed under ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, which aims to create minimally invasive therapies capable of fully regenerating damaged joints.

The initiative awarded the team up to $33.5 million over two years, contingent on progress milestones. Following successful completion of phase one, the project has now advanced to phase two development.

“In two years, we were able to go from a moonshot idea to developing these therapies to demonstrating that they reverse osteoarthritis in animals,” said principal investigator Stephanie Bryant, professor of chemical and biological engineering at CU Boulder. “Our goal is not just to treat pain, but to end this disease.”

Clinical Outlook and Commercialization

Researchers caution that the findings remain in the preclinical stage, and human trials have not yet begun. However, they estimate that clinical trials could begin within approximately 18 months if development continues as planned.

The team has also formed a spinout company, Renovare Therapeutics Inc., to support commercialization efforts and bring the therapies closer to clinical use.

Dr. Evalina Burger of CU Anschutz noted that current treatment options leave many patients with limited choices. “At the moment, the options for many patients are either a massive, expensive surgery or nothing,” she said.

Bryant and her colleagues envision a future in which early-stage osteoarthritis could be treated with a single injection that preserves joint function for years, while more advanced cases could see damaged tissue repaired in a minimally invasive procedure.

“This could be a real game-changer for patients,” Bryant said.